These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 33292843)

  • 1. Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer.
    Sardesai S; Sukumar J; Kassem M; Palettas M; Stephens J; Morgan E; Addison D; Baliga R; Stover DG; VanDeusen J; Williams N; Cherian M; Lustberg M; Wesolowski R; Ramaswamy B
    Cardiooncology; 2020 Nov; 6(1):26. PubMed ID: 33292843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients.
    Qin T; Yuan Z; Peng R; Bai B; Shi Y; Teng X; Liu D; Wang S
    Onco Targets Ther; 2013; 6():341-7. PubMed ID: 23630425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
    Earl H; Hiller L; Vallier AL; Loi S; McAdam K; Hughes-Davies L; Rea D; Howe D; Raynes K; Higgins HB; Wilcox M; Plummer C; Mahler-Araujo B; Provenzano E; Chhabra A; Gasson S; Balmer C; Abraham JE; Caldas C; Hall P; Shinkins B; McCabe C; Hulme C; Miles D; Wardley AM; Cameron DA; Dunn JA
    Health Technol Assess; 2020 Aug; 24(40):1-190. PubMed ID: 32880572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer.
    Yu AF; Yadav NU; Lung BY; Eaton AA; Thaler HT; Hudis CA; Dang CT; Steingart RM
    Breast Cancer Res Treat; 2015 Jan; 149(2):489-95. PubMed ID: 25552363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late-onset cardiotoxicity in patients with HER2-positive metastatic breast cancer receiving trastuzumab-based therapy.
    Alowais SA; Luk SO; Kim EB; Alsuhebany N; Zangardi M
    J Oncol Pharm Pract; 2023 Aug; ():10781552231193149. PubMed ID: 37528623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer.
    Şendur MA; Aksoy S; Yorgun H; Ozdemir N; Yilmaz FM; Yazıcı O; Zungun C; Aytemir K; Zengin N; Altundag K
    Curr Med Res Opin; 2015 Mar; 31(3):547-56. PubMed ID: 25586297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients.
    Guo J; Li Q; Zhang P; Yuan P; Wang J; Ma F; Fan Y; Cai R; Luo Y; Li Q; Xu B
    Chin J Cancer Res; 2019 Oct; 31(5):759-770. PubMed ID: 31814680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital.
    Ayres LR; de Almeida Campos MS; de Oliveira Gozzo T; Martinez EZ; Ungari AQ; de Andrade JM; Pereira LR
    Int J Clin Pharm; 2015 Apr; 37(2):365-72. PubMed ID: 25637407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer.
    Hayashi N; Niikura N; Yamauchi H; Nakamura S; Ueno NT
    Breast Cancer Res Treat; 2013 Jan; 137(2):523-31. PubMed ID: 23184079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study.
    Zhang Y; Mo M; Li JW; Zhou Y; Wu J; Yu KD; Shen ZZ; Shao ZM; Liu GY
    Eur J Surg Oncol; 2016 Aug; 42(8):1146-52. PubMed ID: 27365197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer.
    He X; Ji J; Tian M; Esteva FJ; Hortobagyi GN; Yeung SJ
    Clin Cancer Res; 2019 Dec; 25(24):7388-7395. PubMed ID: 31515457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Chia SKL; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Gokmen E; Bashford A; Ruiz Borrego M; Kim SB; Jakobsen EH; Ciceniene A; Inoue K; Overkamp F; Heijns JB; Armstrong AC; Link JS; Joy AA; Bryce R; Wong A; Moran S; Yao B; Xu F; Auerbach A; Buyse M; Chan A;
    Lancet Oncol; 2017 Dec; 18(12):1688-1700. PubMed ID: 29146401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2- Positive Breast Cancer Patient Population.
    Grela-Wojewoda A; Püsküllüoğlu M; Sas-Korczyńska B; Zemełka T; Pacholczak-Madej R; Wysocki WM; Wojewoda T; Adamczyk A; Lompart J; Korman M; Mucha-Małecka A; Ziobro M; Konduracka E
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis.
    Inno A; Barni S; Ghidini A; Zaniboni A; Petrelli F
    Breast Cancer Res Treat; 2019 Jan; 173(2):247-254. PubMed ID: 30317424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer.
    McLaughlin S; Nakajima E; Bar Y; Hutchinson JA; Shin J; Moy B; Isakoff SJ; Bardia A; Kuter I; Spring LM
    Ther Adv Med Oncol; 2023; 15():17588359221146133. PubMed ID: 36643653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
    Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
    JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.
    Buzdar AU; Suman VJ; Meric-Bernstam F; Leitch AM; Ellis MJ; Boughey JC; Unzeitig GW; Royce ME; Hunt KK
    JAMA Oncol; 2019 Jan; 5(1):45-50. PubMed ID: 30193295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
    Giacchetti S; Hamy AS; Delaloge S; Brain E; Berger F; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Saghatchian M; Lerebours F; Mazouni C; Tembo O; Espié M; Reyal F; Marty M; Asselain B; Pierga JY
    Eur J Cancer; 2017 Apr; 75():323-332. PubMed ID: 28279941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
    Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
    Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of adjuvant trastuzumab on long-term survival of T1N0M0 stage human epidermal growth factor receptor 2 positive breast cancer: a real-world study].
    Sun TH; Lu ZN; Song HT; Sun G
    Zhonghua Zhong Liu Za Zhi; 2023 Jan; 45(1):101-107. PubMed ID: 36709127
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.